BALTIMORE — Lupin Pharmaceuticals Inc. has entered an agreement with Onset Dermatologics LLC for exclusive rights to promote Onset’s Locoid Lotion to pediatricians in the United States.
Lupin said Monday that Locoid Lotion (hydrocortisone butyrate 0.1%) is the nation’s most highly prescribed midpotency steroid brand. However, the company noted, Onset has had minimal promotion of Locoid Lotion to pediatricians, and now Lupin’s specialty sales force will promote the product to provide strategic marketing support.
"This partnership will give pediatricians greater opportunity to utilize Locoid Lotion in their patients while Onset maintains its focus on promoting Locoid to the dermatology community," according to Bob Moccia, president of Rhode Island-based Onset Dermatologics.
The corticosteroid is indicated for the treatment of mild to moderate atopic dermatitis in children ages 3 months and older. Atopic dermatitis is one of the most common skin disorders in young children and has a prevalence of 10% to 20% among children through age 10.
Lupin said the addition of Locoid will expand its product portfolio for the U.S. pediatrics segment, which currently includes Suprax and Alinia for Oral Suspension.
"We are very pleased with the addition of Locoid Lotion to our brand portfolio and are committed to bring meaningful products to the US Pediatric community," stated Vinita Gupta, chief executive officer of Lupin Pharmaceuticals and parent company Lupin Ltd.
